Riccardo Panella

CSO at Resalis Therapeutics

Speaker

Riccardo Panella is an expert in RNA-based drug development, spearheading the first-in-class ASO RES-010 targeting miR-22 for obesity and metabolic disorders. At Resalis Therapeutics he leads preclinical to clinical translation, secures strategic pharma partnerships and shapes the company’s scientific vision.

As Associate Professor at Aalborg University’s Center for RNA Medicine, he heads a team on non-coding RNA in metabolic homeostasis and RNA-targeted interventions. Previously, he was Assistant Research Professor at Desert Research Institute (Reno, NV) studying RNA approaches in cancer metabolism and spent six years at Harvard Medical School’s Cancer Center contributing to RNA-targeting drug discovery.

He is author of multiple patents and peer-reviewed publications and a frequent invited speaker at international conferences on RNA therapeutics and metabolic disease.